Hunt Globally: Deep Research AI Agents for Drug Asset Scouting in Investing, Business Development, and Search & Evaluation

Paper: 2602.15019 Authors: Alisa Vinogradova, Vlad Vinogradov, Luba Greenwood, Ilya Yasny, Dmitry Kobyzev, Shoman Kasbekar, Kong Nguyen, Dmitrii Radkevich, Roman Doronin, Andrey Doronichev Categories: cs.AI, cs.IR

Abstract

The pharmaceutical innovation landscape has fundamentally shifted, with over 85% of patent filings now originating outside the United States and China accounting for nearly half of global filings. This paper addresses a critical gap in AI-powered drug asset discovery: existing deep research agents struggle to achieve high-recall, hallucination-free discovery across heterogeneous multilingual sources. The authors introduce Bioptic Agent, a tree-based self-learning system designed for complete drug asset scouting, alongside a rigorous benchmarking methodology. Testing against leading AI systems including Claude Opus 4.6, GPT-5.2 Pro, Perplexity Deep Research, Gemini 3 Pro, and Exa Websets, Bioptic Agent achieves 79.7% F1 score—substantially outperforming the next-best system at 56.2%. The work demonstrates that additional compute resources correlate with improved performance, validating compute-scaling approaches for complex discovery tasks.

Key Contributions

• Novel Benchmarking Framework: A multilingual multi-agent pipeline for constructing challenging completeness benchmarks using real queries from expert investors, BD professionals, and VCs as priors for conditional query generation
• Bioptic Agent Architecture: A tuned, tree-based self-learning agent specifically optimized for non-hallucinated, complete drug asset scouting across heterogeneous sources
• Comprehensive Evaluation: LLM-as-judge methodology calibrated to expert opinions for grading discovery completeness and accuracy
• Significant Performance Gains: 79.7% F1 score representing a 42% relative improvement over the strongest baseline (Claude Opus 4.6 at 56.2%)
• Compute-Performance Relationship: Empirical evidence that performance scales steeply with additional computational resources

The Global Drug Discovery Challenge

The pharmaceutical industry faces a critical information asymmetry problem. With China representing approximately 30% of global drug development activity spanning over 1,200 novel candidates, and the majority of patent filings occurring outside traditional U.S.-centric channels, investors and business development teams risk missing multi-billion-dollar opportunities. The challenge is compounded by:

Geographic Distribution: Over 85% of patent filings originate outside the U.S., with China alone accounting for nearly 50% of global patent activity. This represents a fundamental shift from historical patterns where U.S. sources dominated pharmaceutical innovation disclosure.

Linguistic Barriers: Many promising drug assets are disclosed primarily through regional, non-English channels including Chinese patent databases, regional regulatory filings, and local scientific publications. Traditional search methodologies optimized for English-language sources systematically miss these assets.

Information Heterogeneity: Drug asset information is scattered across diverse source types—patent databases, clinical trial registries, scientific literature, regulatory filings, company announcements, and conference proceedings—each with different structures, access methods, and disclosure patterns.

Speed Requirements: In competitive deal environments, being first to identify promising assets creates significant value. The time lag between asset disclosure and discovery by Western investors can represent the difference between securing favorable deal terms and missing opportunities entirely.

Current deep research AI agents, while powerful for many tasks, exhibit systematic weaknesses in this domain: incomplete coverage of non-English sources, hallucination of non-existent assets or incorrect details, and inability to achieve the high recall rates necessary for comprehensive scouting.

Methodology and Architecture

The authors develop a two-pronged approach: a rigorous benchmarking methodology to measure performance, and the Bioptic Agent system designed to excel on this benchmark.

Benchmark Construction

The benchmark addresses a fundamental challenge in evaluating drug asset discovery: creating realistic queries paired with verifiable ground-truth assets that reflect actual deal complexity. The methodology involves:

1. Expert Query Collection: Gathering real screening queries from professional investors, business development teams, and venture capital professionals actively engaged in pharmaceutical asset evaluation

2. Conditional Query Generation: Using expert queries as priors to generate benchmark queries that maintain realistic complexity and specificity while enabling systematic evaluation

3. Multilingual Ground Truth: Constructing ground-truth asset sets that are predominantly outside U.S.-centric radar, ensuring the benchmark tests ability to discover “under-the-radar” opportunities

4. Multi-Agent Pipeline: Employing a multilingual multi-agent system to validate ground truth and ensure completeness

Evaluation Framework

The grading system uses LLM-as-judge evaluation calibrated against expert human opinions. This approach balances scalability with accuracy, enabling systematic comparison across multiple systems while maintaining alignment with how domain experts would assess discovery quality. The evaluation focuses on:

• Recall: Proportion of ground-truth assets successfully discovered
• Precision: Accuracy of discovered assets (absence of hallucinations)
• F1 Score: Harmonic mean balancing recall and precision

Bioptic Agent Design

While the paper doesn’t exhaustively detail the architecture, key design principles include:

• Tree-Based Search: Structured exploration strategy that systematically covers the search space rather than relying on single-path retrieval
• Self-Learning: Adaptive mechanisms that improve performance through experience with the domain
• Multilingual Capability: Native support for processing and reasoning across multiple languages, particularly English and Chinese
• Hallucination Prevention: Explicit mechanisms to ground discoveries in verifiable sources and avoid generating false positives

The tree-based approach likely enables the agent to explore multiple hypotheses in parallel, backtrack when paths prove unproductive, and synthesize information across diverse sources—capabilities essential for comprehensive asset discovery.

Results and Performance Analysis

The experimental results reveal substantial performance gaps between systems:

System	F1 Score	Performance Gap
Bioptic Agent	79.7%	Baseline
Claude Opus 4.6	56.2%	-29.5%
Gemini 3 Pro + Deep Research	50.6%	-36.5%
GPT-5.2 Pro	46.6%	-41.5%
Perplexity Deep Research	44.2%	-44.5%
Exa Websets	26.9%	-66.2%

Key Observations

The 79.7% F1 score achieved by Bioptic Agent represents a 42% relative improvement over the strongest baseline. This gap is particularly significant given that the baseline systems represent state-of-the-art deep research capabilities from leading AI labs.

The performance distribution suggests that general-purpose deep research agents, while capable, lack domain-specific optimizations necessary for pharmaceutical asset discovery. The gap between Claude Opus 4.6 (56.2%) and Gemini 3 Pro (50.6%) is relatively modest compared to the gap between these systems and Bioptic Agent, suggesting that domain specialization matters more than general model capabilities.

Compute Scaling

A critical finding is that Bioptic Agent’s performance improves steeply with additional computational resources. This validates the compute-scaling hypothesis: for complex discovery tasks, allocating more compute to thorough search and verification yields better results. This has important implications:

• Economic Trade-offs: Organizations can tune compute allocation based on the value of comprehensive discovery versus cost constraints
• Performance Ceiling: The steep scaling curve suggests current performance may not represent a fundamental ceiling, with room for improvement through additional compute
• Architectural Validation: The tree-based search architecture effectively utilizes additional compute, unlike approaches that might plateau

Error Analysis

While specific error patterns aren’t detailed in the abstract, the F1 scores suggest different failure modes across systems. The relatively low performance of Exa Websets (26.9%) suggests that pure retrieval-based approaches struggle with the complexity of pharmaceutical asset discovery. The moderate performance of general-purpose deep research agents (44-56%) indicates they achieve reasonable recall or precision individually but struggle to optimize both simultaneously.

Implications for Pharmaceutical Investment and Business Development

The research has immediate practical implications for how pharmaceutical investment and business development teams approach asset discovery:

Competitive Advantage: Organizations deploying specialized AI agents for asset scouting can achieve systematic advantages in deal flow. The 42% performance improvement translates directly to discovering more opportunities earlier in their lifecycle.

Risk Mitigation: Comprehensive scouting reduces the multi-billion-dollar risk of missing transformative assets. In an industry where single assets can represent $1B+ in value, even modest improvements in discovery completeness justify significant investment.

Resource Allocation: The compute-scaling relationship provides a framework for optimizing resource allocation. Teams can make informed decisions about when to invest additional compute for critical searches versus accepting faster but less complete results for routine monitoring.

Geographic Expansion: The demonstrated capability to effectively search non-U.S., multilingual sources enables Western investors and companies to systematically access the growing Chinese and Asian pharmaceutical innovation ecosystems.

Process Transformation: Moving from human-expert-driven scouting to AI-augmented discovery allows experts to focus on evaluation and deal execution rather than exhaustive search, potentially accelerating deal cycles.

Technical Insights and Future Directions

Several technical insights emerge from this work:

Domain Specialization Matters: The performance gap between Bioptic Agent and general-purpose systems demonstrates that domain-specific architecture and training provide substantial benefits. This suggests a broader principle: for high-stakes, specialized tasks, purpose-built agents outperform general-purpose systems even when the latter have larger scale or more sophisticated base models.

Tree-Based Search for Discovery: The tree-based approach appears particularly well-suited for discovery tasks requiring comprehensive coverage. Unlike linear search or single-path retrieval, tree-based methods can systematically explore the search space while managing computational costs.

Hallucination Prevention: Achieving high precision alongside high recall in a domain with verifiable ground truth requires explicit hallucination prevention mechanisms. This remains a critical challenge for AI systems in high-stakes applications.

Multilingual Reasoning: Effective pharmaceutical asset discovery requires genuine multilingual capability, not just translation. The system must understand domain concepts across languages and synthesize information from sources in different languages.

Future Research Directions

• Broader Domain Coverage: Extending beyond pharmaceuticals to other industries with similar geographic and linguistic discovery challenges
• Real-Time Monitoring: Adapting the approach for continuous monitoring rather than one-time searches
• Explainability: Developing methods to explain why specific assets were surfaced and how confidence levels are determined
• Human-AI Collaboration: Optimizing the interface between AI discovery and human expert evaluation
• Compute Efficiency: Investigating whether architectural improvements can achieve similar performance with reduced computational requirements

Takeaways

1. Geographic Shift in Innovation: Over 85% of pharmaceutical patent filings now originate outside the U.S., with China accounting for nearly half, creating systematic blind spots for traditional U.S.-centric discovery approaches.

2. Specialized Agents Outperform General Systems: Bioptic Agent’s 79.7% F1 score represents a 42% relative improvement over the best general-purpose deep research AI (Claude Opus 4.6 at 56.2%), demonstrating the value of domain-specific optimization.

3. Compute Scaling Validates Investment: Performance improves steeply with additional computational resources, providing a clear framework for organizations to optimize the trade-off between discovery completeness and cost.

4. Multilingual Capability is Essential: Effective drug asset discovery requires native multilingual processing, not just translation, to access the 30% of global drug development activity occurring in China and other non-English-speaking regions.

5. Benchmarking Methodology Advances the Field: The paper’s approach to constructing realistic benchmarks using expert queries as priors and LLM-as-judge evaluation calibrated to expert opinions provides a template for evaluating AI systems in other specialized domains.

6. High-Stakes Applications Demand Hallucination Prevention: Achieving 79.7% F1 requires balancing high recall with precision, demonstrating that preventing false positives is as critical as comprehensive discovery in pharmaceutical investment contexts.

7. Tree-Based Search Enables Comprehensive Coverage: The architectural choice of tree-based exploration appears particularly effective for discovery tasks requiring systematic coverage of heterogeneous, multilingual sources.